← Back to Analyst Consensus 
BBIO Buy
BridgeBio Pharma, Inc.
Current Price —
Implied Upside —
Analysts 29
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 4 reiterations from 4 firms
Next Earnings
Oct 29, 2026 (2 days)
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Oct 21, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Oct 19, 2026 | Citigroup | maintain | Neutral → Neutral | — | 54% |
| Oct 19, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Oct 7, 2026 | Barclays | maintain | Overweight → Overweight | — | 53% |
| Sep 10, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 2, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Sep 1, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Aug 12, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Aug 12, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 12, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Aug 11, 2026 | B of A Securities | maintain | Buy → Buy | — | 53% |
| Aug 11, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 11, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| Aug 11, 2026 | Piper Sandler | maintain | Overweight → Overweight | — | 54% |
| Aug 11, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jul 16, 2026 | Citigroup | maintain | Neutral → Neutral | — | 54% |
| Jul 13, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Jun 16, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Jun 3, 2026 | Canaccord Genuity | initiate | — → Buy | — | 48% |
| May 28, 2026 | Morgan Stanley | maintain | Overweight → Overweight | — | 54% |
| May 28, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| May 26, 2026 | Raymond James | downgrade | Outperform → Market Perform | — | 53% |
| May 19, 2026 | Citigroup | initiate | — → Neutral | — | 54% |
| May 11, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 8, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Apr 29, 2026 | Truist Securities | maintain | Buy → Buy | — | 54% |
| Apr 29, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 28, 2026 | Mizuho | reiterate | Outperform → Outperform | — | 52% |
| Apr 27, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Apr 9, 2026 | RBC Capital | initiate | — → Outperform | — | 55% |
| Mar 18, 2026 | Mizuho | maintain | Outperform → Outperform | — | 52% |
| Mar 10, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Mar 10, 2026 | William Blair | initiate | — → Outperform | — | 47% |
| Feb 25, 2026 | Truist Securities | maintain | Buy → Buy | $95 | 54% |
| Feb 25, 2026 | Oppenheimer | maintain | Outperform → Outperform | $81 | 52% |
| Feb 25, 2026 | Morgan Stanley | maintain | Overweight → Overweight | $98 | 54% |
| Feb 25, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | $125 | 58% |
| Feb 17, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | $100 | 44% |
| Feb 13, 2026 | Oppenheimer | maintain | Outperform → Outperform | $83 | 52% |
| Feb 13, 2026 | Wells Fargo | maintain | Overweight → Overweight | $98 | 54% |
| Jan 28, 2026 | Barclays | initiate | — → Overweight | $80 | 53% |
| Jan 20, 2026 | Wells Fargo | maintain | Overweight → Overweight | $88 | 54% |
| Jan 8, 2026 | Truist Securities | maintain | Buy → Buy | $86 | 54% |
| Jan 6, 2026 | Morgan Stanley | initiate | — → Overweight | $96 | 54% |
| Dec 15, 2025 | Leerink Partners | maintain | Outperform → Outperform | $86 | 51% |
| Dec 11, 2025 | Bernstein | initiate | — → Outperform | $94 | 52% |
| Nov 11, 2025 | Wells Fargo | maintain | Overweight → Overweight | $84 | 54% |
| Nov 7, 2025 | JP Morgan | maintain | Overweight → Overweight | $77 | 54% |
| Nov 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $90 | 44% |
| Oct 31, 2025 | Goldman Sachs | maintain | Buy → Buy | $100 | 54% |
Price Target Trend
Jul 14, 2026 Oct 27, 2026
EPS Estimates
+1q —
+1y —
0y —
0q —
Cross-Platform Signals
No cross-platform signals in the last 90 days